Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 41,200 KRW
Change Today -750.00 / -1.79%
Volume 29.7K
As of 12:32 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

neopharm co ltd (092730) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/15 - 53,600
52 Week Low
08/4/14 - 10,250
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOPHARM CO LTD (092730)

Related News

No related news articles were found.

neopharm co ltd (092730) Related Businessweek News

No Related Businessweek News Found

neopharm co ltd (092730) Details

NeoPharm Co., Ltd. manufactures and sells skin care products in South Korea and internationally. The company offers products for dry and sensitive skin under the ATOPALM brand; and products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand. It also provides body and skin care products under the DERMA-B brand; and sport care products for athletes under the MISSION ATHELETCARE brand, as well as MAXFIT, a care for muscle and skin conditions. The company was founded in 2000 and is based in Daejeon, South Korea.

Founded in 2000

neopharm co ltd (092730) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neopharm co ltd (092730) Key Developments

LEO Pharma A/S Enters Supply and Distribution Agreement with NeoPharm Co., Ltd. on Non-Prescription Skin Care Solutions

LEO Pharma A/S and NeoPharm Co. Ltd. announced that the companies have entered into a 10 year's agreement of supply and distribution of a selection of skin care products within NeoPharm's range of products. Under the terms of the agreement, products will be manufactured and supplied by NeoPharm and marketed and distributed by LEO Pharma as non-prescription skin care under a LEO Pharma trademark. NeoPharm has developed the products using their proprietary technology MLE (Multi-Lamellar Emulsion), Defensamide and ADfence-P. LEO Pharma will have the rights to market the products globally - except for Korea, Thailand, Indonesia, Pakistan, Singapore, Malaysia, UAE and the Philippines. LEO Pharma is increasing its focus on meeting the unmet needs of people living with skin diseases. By entering partnerships with innovative companies, like NeoPharm, LEO Pharma wants to bring new dermatology solutions to patients - faster. Spain will be the first of several markets to gain access to the new LEO Pharma emollients portfolio. This is expected to happen during 2015.

Neopharm Co Ltd, Annual General Meeting, Mar 27, 2015

Neopharm Co Ltd, Annual General Meeting, Mar 27, 2015., at 09:00 Korea Standard Time. Location: 309-8 in Yuseong Techno 2. Agenda: To consider audit reports, sales reports, financial statements and the appropriation of retained earnings for the year ended December 31, 2014; to approve dividend KRW 205 per share; to consider board changes; to consider directors' remuneration; and to approve audit fees limit.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
092730:KS 41,200.00 KRW -750.00

092730 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 092730.
View Industry Companies

Industry Analysis


Industry Average

Valuation 092730 Industry Range
Price/Earnings 87.2x
Price/Sales 10.0x
Price/Book 9.0x
Price/Cash Flow 83.1x
TEV/Sales 10.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOPHARM CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at